Dyadic International (DYAI) Competitors $0.94 -0.03 (-3.09%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$0.94 0.00 (-0.43%) As of 04:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYAI vs. GLSI, FATE, PLX, NKTX, CRBU, ACTU, CRDL, ATOS, KRRO, and VXRTShould you be buying Dyadic International stock or one of its competitors? The main competitors of Dyadic International include Greenwich LifeSciences (GLSI), Fate Therapeutics (FATE), Protalix BioTherapeutics (PLX), Nkarta (NKTX), Caribou Biosciences (CRBU), Actuate Therapeutics (ACTU), Cardiol Therapeutics (CRDL), Atossa Genetics (ATOS), Korro Bio (KRRO), and Vaxart (VXRT). These companies are all part of the "pharmaceutical products" industry. Dyadic International vs. Its Competitors Greenwich LifeSciences Fate Therapeutics Protalix BioTherapeutics Nkarta Caribou Biosciences Actuate Therapeutics Cardiol Therapeutics Atossa Genetics Korro Bio Vaxart Dyadic International (NASDAQ:DYAI) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation. Which has more volatility & risk, DYAI or GLSI? Dyadic International has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Which has better earnings & valuation, DYAI or GLSI? Dyadic International has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyadic International$3.49M8.10-$5.81M-$0.20-4.70Greenwich LifeSciencesN/AN/A-$15.79M-$1.26-7.84 Is DYAI or GLSI more profitable? Greenwich LifeSciences has a net margin of 0.00% compared to Dyadic International's net margin of -163.94%. Dyadic International's return on equity of -233.69% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Dyadic International-163.94% -233.69% -59.37% Greenwich LifeSciences N/A -450.87%-333.18% Do insiders & institutionals believe in DYAI or GLSI? 28.0% of Dyadic International shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 29.5% of Dyadic International shares are held by insiders. Comparatively, 51.7% of Greenwich LifeSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer DYAI or GLSI? In the previous week, Dyadic International had 2 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 2 mentions for Dyadic International and 0 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 0.94 beat Dyadic International's score of 0.93 indicating that Greenwich LifeSciences is being referred to more favorably in the news media. Company Overall Sentiment Dyadic International Positive Greenwich LifeSciences Positive Do analysts recommend DYAI or GLSI? Dyadic International currently has a consensus price target of $6.00, suggesting a potential upside of 538.30%. Greenwich LifeSciences has a consensus price target of $39.00, suggesting a potential upside of 294.74%. Given Dyadic International's higher probable upside, equities research analysts plainly believe Dyadic International is more favorable than Greenwich LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyadic International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryDyadic International beats Greenwich LifeSciences on 9 of the 13 factors compared between the two stocks. Get Dyadic International News Delivered to You Automatically Sign up to receive the latest news and ratings for DYAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYAI vs. The Competition Export to ExcelMetricDyadic InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.19M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-4.7021.3126.1919.90Price / Sales8.10278.47414.04113.66Price / CashN/A41.4736.1356.90Price / Book11.757.518.025.38Net Income-$5.81M-$55.05M$3.15B$248.50M7 Day Performance-5.53%2.07%1.48%2.06%1 Month Performance-6.47%4.84%3.67%4.86%1 Year Performance-36.05%5.37%34.68%20.24% Dyadic International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYAIDyadic International2.6223 of 5 stars$0.94-3.1%$6.00+538.3%-35.2%$29.19M$3.49M-4.707News CoverageHigh Trading VolumeGLSIGreenwich LifeSciences1.9048 of 5 stars$9.07+0.9%$39.00+330.0%-43.8%$120.18MN/A-7.203FATEFate Therapeutics4.0963 of 5 stars$1.12+7.7%$3.83+242.3%-65.2%$119.19M$13.63M-0.75550Gap UpPLXProtalix BioTherapeutics2.8782 of 5 stars$1.48-3.9%$15.00+913.5%+33.3%$117.82M$59.76M-11.38200NKTXNkarta2.2621 of 5 stars$1.66flat$14.33+763.5%-66.9%$117.79MN/A-1.10140News CoverageCRBUCaribou Biosciences2.0773 of 5 stars$1.26flat$8.50+574.6%-14.4%$117.19M$9.99M-0.78100ACTUActuate Therapeutics2.9154 of 5 stars$6.11+2.5%$20.50+235.5%N/A$116.93MN/A0.0010Insider TradeHigh Trading VolumeCRDLCardiol Therapeutics2.5122 of 5 stars$1.36-3.5%$8.00+488.2%-29.1%$116.54MN/A-4.0020Positive NewsGap UpATOSAtossa Genetics2.1677 of 5 stars$0.83-5.6%$6.17+643.0%-27.8%$113.61MN/A-3.958Positive NewsKRROKorro Bio2.5427 of 5 stars$12.49+3.8%$102.43+720.1%-60.5%$112.97M$2.27M-1.3270Positive NewsVXRTVaxart2.359 of 5 stars$0.45-8.6%$3.00+563.7%-35.4%$112.90M$28.70M-1.67120Positive NewsGap Down Related Companies and Tools Related Companies Greenwich LifeSciences Alternatives Fate Therapeutics Alternatives Protalix BioTherapeutics Alternatives Nkarta Alternatives Caribou Biosciences Alternatives Actuate Therapeutics Alternatives Cardiol Therapeutics Alternatives Atossa Genetics Alternatives Korro Bio Alternatives Vaxart Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYAI) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyadic International Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyadic International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
